Mandating gardasil vaccine
Sponsored by Senator Julie Morrison of Deerfield Amends the Communicable Disease Prevention Act.Provides that the Department of Public Health shall adopt a rule requiring students, upon entering the 6th grade of any public, private, or parochial school, to receive a human papillomavirus (HPV) vaccination.Parents at this time can get the advise of the child’s physician regarding this vaccine. Since it is not communicable in a normal school setting, the vaccine should not be required for school attendance. prompting research and development of a vaccine to prevent human papillomavirus (HPV).Invasive cervical cancer from an unresolved HPV infection can take decades The FDA also permitted Merck to use Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS), an aluminum adjuvant, in lieu of a saline placebo, as a control in pre-licensure clinical trials of the original Gardasil.Yet, even with studies that linked aluminum to inflammation and chronic health issues, Merck was granted permission to use it as a control in pre-licensure safety studies.
[email protected]@[email protected]@[email protected]@[email protected]@gov [email protected]@[email protected]@Sample email: Subject: Oppose SB1659 Mandating HPV Vaccine Vote “NO” to mandating SB1659 for all 6th grade students. Others side effects include: auto immune disease, seizures, Guillain-Barre Syndrome (paralysis) and death.These treatment options continue to be the standard of care for screening and prevention of cervical cancer they show any clinical benefit to the patient.Approval is based on findings associated with use of a “surrogate endpoint”, such as a physical marker, laboratory finding such as antibody levels or “other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit.” In other words, Gardasil did not have to demonstrate true effectiveness – prevention of cervical cancer – prior to being determined to be effective and granted approval and licensed by the FDA.Issues included clinical trial methods that involved use of bioreactive active placebos and known safety problems associated with injected aluminum, safety signals reported during pre-licensure clinical trials, inappropriate small sample sizes of the target population slated for vaccination, and an absence of proof of effectiveness.
Within weeks of Gardasil’s FDA approval, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to recommend three doses of the vaccine for all 11 and 12 year old girls with a “catch up” schedule for females between the age of 13 and 26.
The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) first discussed HPV vaccine and issues related to assessing effectiveness at its licensure at the November 2001 meeting.